CN103435546B - 制备异喹啉化合物的方法 - Google Patents

制备异喹啉化合物的方法 Download PDF

Info

Publication number
CN103435546B
CN103435546B CN201310302822.0A CN201310302822A CN103435546B CN 103435546 B CN103435546 B CN 103435546B CN 201310302822 A CN201310302822 A CN 201310302822A CN 103435546 B CN103435546 B CN 103435546B
Authority
CN
China
Prior art keywords
compound
formula
hydrogen
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310302822.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103435546A (zh
Inventor
迈克尔·道格拉斯·汤普森
朴贞玟
迈克尔·P·阿伦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen China Medical Technology Development Co Ltd
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48857024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103435546(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Priority to CN201610421229.1A priority Critical patent/CN106083719B/zh
Publication of CN103435546A publication Critical patent/CN103435546A/zh
Application granted granted Critical
Publication of CN103435546B publication Critical patent/CN103435546B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201310302822.0A 2012-07-16 2013-07-15 制备异喹啉化合物的方法 Active CN103435546B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610421229.1A CN106083719B (zh) 2012-07-16 2013-07-15 制备异喹啉化合物的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672191P 2012-07-16 2012-07-16
US61/672191 2012-07-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610421229.1A Division CN106083719B (zh) 2012-07-16 2013-07-15 制备异喹啉化合物的方法

Publications (2)

Publication Number Publication Date
CN103435546A CN103435546A (zh) 2013-12-11
CN103435546B true CN103435546B (zh) 2016-08-10

Family

ID=48857024

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310302822.0A Active CN103435546B (zh) 2012-07-16 2013-07-15 制备异喹啉化合物的方法
CN201610421229.1A Active CN106083719B (zh) 2012-07-16 2013-07-15 制备异喹啉化合物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610421229.1A Active CN106083719B (zh) 2012-07-16 2013-07-15 制备异喹啉化合物的方法

Country Status (22)

Country Link
US (2) US9340511B2 (enExample)
EP (2) EP3219706A1 (enExample)
JP (1) JP6196671B2 (enExample)
KR (1) KR102145272B1 (enExample)
CN (2) CN103435546B (enExample)
AU (1) AU2013290437B2 (enExample)
BR (1) BR112015001106B1 (enExample)
CA (1) CA2879238C (enExample)
CY (1) CY2022018I1 (enExample)
DK (1) DK2872487T3 (enExample)
ES (1) ES2631655T3 (enExample)
HU (2) HUE034409T2 (enExample)
IL (1) IL236625B (enExample)
IN (1) IN2015KN00265A (enExample)
MX (1) MX350922B (enExample)
MY (1) MY171483A (enExample)
NZ (1) NZ704660A (enExample)
PL (1) PL2872487T3 (enExample)
PT (1) PT2872487T (enExample)
SG (1) SG11201500234YA (enExample)
WO (1) WO2014014834A1 (enExample)
ZA (1) ZA201500664B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109776415A (zh) * 2019-03-07 2019-05-21 福建南方济民医药研发中心有限公司 一种Roxadustat中间体的制备方法

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
EP3219706A1 (en) 2012-07-16 2017-09-20 Fibrogen, Inc. Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
AU2013290438C1 (en) 2012-07-16 2019-01-03 Kyntra Bio, Inc. Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
HRP20200615T1 (hr) 2013-06-06 2020-07-10 Fibrogen, Inc. Farmaceutske formulacije inhibitora hif hidroksilaze
CN103694172A (zh) * 2013-12-26 2014-04-02 辽宁亿灵科创生物医药科技有限公司 含氮杂芳基化合物的衍生物
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
WO2016045125A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CN104447547B (zh) * 2014-11-10 2017-04-19 苏州康润医药有限公司 4‑氨基异喹啉‑8‑甲酸甲酯的合成方法
CN106146490B (zh) * 2015-03-27 2018-10-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN104892509B (zh) * 2015-06-04 2018-03-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CN106478503A (zh) * 2016-09-29 2017-03-08 上海勋和医药科技有限公司 Roxadustat中间体的制备方法
CZ2016627A3 (cs) 2016-10-07 2018-04-18 Zentiva, K.S. Způsob přípravy (7-fenoxy-4-hydroxy-1-methylisochinolin-3-karbonyl)glycinu (roxadustatu) a jeho intermediátů založený na souběžném otevírání oxazolového kruhu, štěpení etheru a tvorbě iminu
CN107954931B (zh) * 2016-10-17 2021-06-22 上海医药集团青岛国风药业股份有限公司 一种诺得司他的制备方法
CN110225753B (zh) 2017-01-28 2022-12-09 金凯(辽宁)生命科技股份有限公司 用于制备5-苯氧基-1(3h)异苯并呋喃酮的方法
CA3083672A1 (en) * 2017-12-01 2019-06-06 Dr. Reddy's Laboratories Limited Process for the preparation of roxadustat and its intermediates
CN109956870A (zh) * 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
CN110218184B (zh) * 2018-03-01 2022-09-27 广东东阳光药业有限公司 诺德司他共晶及其制备方法
CN110272386B (zh) * 2018-03-16 2022-09-09 上海医药集团青岛国风药业股份有限公司 一种诺得司他的制备方法
CN110526813B (zh) * 2018-05-24 2022-06-28 杭州科巢生物科技有限公司 异喹啉化合物的制备方法及其中间体
CN111978225B (zh) 2018-06-05 2022-03-04 沈阳化工大学 一种三氟乙基硫醚（亚砜）取代苯类化合物及其用途
KR20210108367A (ko) 2018-11-09 2021-09-02 비바체 테라퓨틱스, 인크. 비시클릭 화합물
MX2021012638A (es) 2019-04-16 2022-01-04 Vivace Therapeutics Inc Compuestos biciclicos.
RU2709493C1 (ru) * 2019-08-01 2019-12-18 Марат Феликсович Фазылов Способ получения роксадустата
WO2021026307A1 (en) 2019-08-07 2021-02-11 Teva Pharmaceuticals International Gmbh Processes for the preparation of roxadustat and intermediates thereof
CN112441975B (zh) * 2019-09-03 2023-10-31 西藏嘉信景天药业有限公司 一种罗沙司他重要中间体的制备方法
CN112679430B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
WO2021073623A1 (zh) * 2019-10-18 2021-04-22 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN112679431B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法
CN113444042A (zh) * 2020-03-27 2021-09-28 南京海润医药有限公司 一种罗沙司他的制备方法
WO2021214785A1 (en) 2020-04-21 2021-10-28 Mylan Laboratories Limited Improved process for the preparation of roxadustat
CN111533691A (zh) * 2020-06-08 2020-08-14 重庆三圣实业股份有限公司 一种罗沙司他的制备方法
CN113801060B (zh) 2020-06-13 2025-06-27 苏州鹏旭医药科技有限公司 一种多取代异喹啉化合物的制备方法
US12410140B2 (en) 2020-06-19 2025-09-09 Jumpcan (Shanghai) Medical Technology Co., Ltd Method for synthesis of roxadustat and intermediate thereof, and intermediate thereof
CN112409258B (zh) * 2020-11-20 2025-11-25 杭州科巢生物科技有限公司 一种罗沙司他的制备方法
CN114644589A (zh) * 2020-12-17 2022-06-21 鲁南制药集团股份有限公司 一种化合物n-[（4-羟基--1-甲基-3-异喹啉基）羰基]-甘氨酸的制备方法
CN114671807B (zh) * 2020-12-24 2026-03-24 联化科技（德州）有限公司 一种1-取代异喹啉类化合物的制备方法
US20230101768A1 (en) * 2021-08-13 2023-03-30 The Board Of Regents Of The University Of Texas System Method to treat manganese toxicity and manganese-induced parkinsonism in humans
CN116178260A (zh) * 2021-11-26 2023-05-30 四川国康药业有限公司 一种治疗肾性贫血的化合物及其制备方法
CN115124467A (zh) * 2022-07-11 2022-09-30 天津力生制药股份有限公司 一种罗沙司他关键中间体的制备方法
CN117105862B (zh) * 2023-07-26 2025-12-30 北京福元医药股份有限公司 一种罗沙司他及其中间体的制备方法
CN117486797A (zh) * 2023-11-23 2024-02-02 传健生物医药(厦门)有限公司 一种罗沙司他关键中间体及罗沙司他的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1218802A (zh) * 1997-10-20 1999-06-09 德国赫彻斯特马里奥罗塞尔有限公司 取代的异喹啉-3-甲酰胺类化合物,其制备方法及其作为药物的用途
WO2003053997A2 (en) * 2001-12-06 2003-07-03 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)
WO2004052285A2 (en) * 2002-12-06 2004-06-24 Fibrogen, Inc. Fat regulation
US20040254215A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and methods of use thereof
CN101374815A (zh) * 2006-01-27 2009-02-25 菲布罗根有限公司 使低氧诱导因子（hif）稳定的氰基异喹啉化合物

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
ATE149485T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
DK0650961T3 (da) 1993-11-02 1997-09-15 Hoechst Ag Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
IL129344A0 (en) 1996-11-27 2000-02-17 Du Pont Pharm Co Novel integrin receptor antagonists
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
WO2002101073A2 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
CA2450625A1 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005009962A1 (en) 2003-07-15 2005-02-03 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
EP1658074B1 (en) 2003-08-01 2012-11-07 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
ZA200610164B (en) 2004-05-28 2008-02-27 Fibrogen Inc HIF prolyl hydroxylase activity assay
AP2007004047A0 (en) * 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
US8703795B2 (en) 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
AU2006254897A1 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
MX2007016160A (es) 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
CA2631197C (en) * 2005-11-28 2013-01-29 Commvault Systems, Inc. Systems and methods for data management
WO2007097929A1 (en) 2006-02-16 2007-08-30 Fibrogen, Inc. Compounds and methods for treatment of stroke
BRPI0710527B8 (pt) 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
US20140171465A1 (en) 2011-01-13 2014-06-19 Fibrogen, Inc. Methods For Increasing Reticulocyte Hemoglobin Content
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
CN104024227B8 (zh) * 2011-07-22 2025-07-29 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
AU2013290438C1 (en) 2012-07-16 2019-01-03 Kyntra Bio, Inc. Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EP3219706A1 (en) 2012-07-16 2017-09-20 Fibrogen, Inc. Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
AU2014209319B2 (en) 2013-01-24 2018-04-19 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
HRP20200615T1 (hr) 2013-06-06 2020-07-10 Fibrogen, Inc. Farmaceutske formulacije inhibitora hif hidroksilaze

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1218802A (zh) * 1997-10-20 1999-06-09 德国赫彻斯特马里奥罗塞尔有限公司 取代的异喹啉-3-甲酰胺类化合物,其制备方法及其作为药物的用途
WO2003053997A2 (en) * 2001-12-06 2003-07-03 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)
WO2004052285A2 (en) * 2002-12-06 2004-06-24 Fibrogen, Inc. Fat regulation
US20040254215A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and methods of use thereof
CN1816527A (zh) * 2003-06-06 2006-08-09 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
CN101374815A (zh) * 2006-01-27 2009-02-25 菲布罗根有限公司 使低氧诱导因子（hif）稳定的氰基异喹啉化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109776415A (zh) * 2019-03-07 2019-05-21 福建南方济民医药研发中心有限公司 一种Roxadustat中间体的制备方法
CN109776415B (zh) * 2019-03-07 2020-11-17 福建南方制药股份有限公司 一种Roxadustat中间体的制备方法

Also Published As

Publication number Publication date
KR102145272B1 (ko) 2020-08-18
MY171483A (en) 2019-10-15
CY2022018I2 (el) 2023-01-05
IL236625B (en) 2019-01-31
NZ704660A (en) 2017-10-27
US20150175550A1 (en) 2015-06-25
CA2879238C (en) 2021-08-10
ES2631655T3 (es) 2017-09-01
EP3219706A1 (en) 2017-09-20
US9340511B2 (en) 2016-05-17
ZA201500664B (en) 2017-08-30
KR20150058147A (ko) 2015-05-28
WO2014014834A1 (en) 2014-01-23
CY2022018I1 (el) 2023-01-05
BR112015001106B1 (pt) 2021-11-09
EP2872487B1 (en) 2017-04-26
MX350922B (es) 2017-09-25
US20160194285A1 (en) 2016-07-07
SG11201500234YA (en) 2015-02-27
PT2872487T (pt) 2017-05-15
AU2013290437A1 (en) 2015-02-19
AU2013290437B2 (en) 2017-11-02
CN103435546A (zh) 2013-12-11
CN106083719B (zh) 2019-10-18
EP2872487A1 (en) 2015-05-20
HUS2200030I1 (hu) 2022-07-28
DK2872487T3 (en) 2017-06-06
PL2872487T3 (pl) 2017-09-29
IN2015KN00265A (enExample) 2015-06-12
JP6196671B2 (ja) 2017-09-13
BR112015001106A2 (pt) 2017-06-27
CN106083719A (zh) 2016-11-09
US9708269B2 (en) 2017-07-18
HUE034409T2 (en) 2018-02-28
CA2879238A1 (en) 2014-01-23
MX2015000505A (es) 2015-07-17
IL236625A0 (en) 2015-02-26
JP2015524409A (ja) 2015-08-24

Similar Documents

Publication Publication Date Title
CN103435546B (zh) 制备异喹啉化合物的方法
TWI715658B (zh) 二氫嘧啶並環化合物的晶型、製備方法和中間體
WO2015007249A1 (zh) N-烷基色胺酮衍生物及其制备方法和应用
CN105503627B (zh) 一种新型棉酚希夫碱衍生物及其制备方法与应用
CN104860923B (zh) 富马酸沃诺拉赞的制备方法
CN106749259A (zh) 一种环戊基嘧啶并吡咯类化合物的合成方法
CN1190436C (zh) 一种制备格拉司琼及其盐的方法
CN110963959B (zh) 一种合成n-保护及非保护的3-羟基-4,4-二甲基哌啶的制备方法
HK1231055B (zh) 制备异喹啉化合物的方法
HK1231055A1 (en) Process for making isoquinoline compounds
CN116496239A (zh) 一种维奈托克关键中间体及原料药的合成方法
CN115703712A (zh) 5,8-二氨基-3,4-二氢-2h-1-萘酮的合成方法以及其中采用的中间体化合物
CN107098844B (zh) 一种c-5位硝基取代的酰基吲哚啉类化合物的合成方法
CN103664781A (zh) 盐酸屈他维林晶型i和晶型ii及制备方法
CN113773270B (zh) 一种3-(5-甲基-4-苯基异恶唑-3-基）苯磺酰胺的合成方法
WO2026077192A1 (zh) 一种新型含四氢荼-1-胺类结构的 mao-b 抑制剂制备及其用途
CN107337667B (zh) 一种用于治疗多发性骨髓瘤的来那度胺的制备工艺
CN104860946A (zh) Ccr5拮抗剂的制备方法
CN115611901A (zh) 一种氮杂䓬类化合物或其药学上可接受的盐及其制备方法和应用
CN104520272B (zh) 多奈哌齐衍生物
CN115611894A (zh) 一种含氮螺环化合物或其药学上可接受的盐及其制备方法和应用
CN103819433A (zh) 一种哌嗪-苯并呋喃类化合物的合成方法
CN104693058A (zh) 一种辛酰苯胺酸甲酯制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200827

Address after: Room 101-601, unit 2, building 7, yard 88, Kechuang 6th Street, Daxing District, Beijing

Patentee after: FIBROGEN (CHINA) MEDICINE TECHNOLOGY DEVELOPMENT Co.,Ltd.

Address before: California, USA

Patentee before: FibroGen, Inc.

TR01 Transfer of patent right